Tropical Medicine Cluster, Chulalongkorn University, Bangkok, Thailand.
University of the East Ramon Magsaysay Memorial Medical Center, Quezon City, Philippines.
Hum Vaccin Immunother. 2022 Nov 30;18(6):2110759. doi: 10.1080/21645515.2022.2110759. Epub 2022 Sep 9.
Invasive meningococcal disease (IMD) imposes a significant burden on the global community due to its high case fatality rate (4-20%) and the risk of long-term sequelae for one in five survivors. An expert group meeting was held to discuss the epidemiology of IMD and immunization policies in Malaysia, Philippines, Thailand, and Vietnam. Most of these countries do not include meningococcal immunization in their routine vaccination programs, except for high-risk groups such as immunocompromised people and pilgrims. It is difficult to estimate the epidemiology of IMD in the highly diverse Asia-Pacific region, but available evidence indicate serogroup B is increasingly dominant. Disease surveillance systems differ by country. IMD is not a notifiable disease in some of them. Without an adequate surveillance system in the region, the risk and the burden of IMD might well be underestimated. With the availability of new combined meningococcal vaccines and the World Health Organization roadmap to defeat bacterial meningitis by 2030, a better understanding of the epidemiology of IMD in the Asia-Pacific region is needed.
侵袭性脑膜炎球菌病(IMD)由于其高病死率(4-20%)和五分之一幸存者存在长期后遗症的风险,给全球社会带来了巨大负担。一个专家组会议讨论了马来西亚、菲律宾、泰国和越南的 IMD 流行病学和免疫政策。除了免疫功能低下者和朝圣者等高危人群外,这些国家大多数都没有将脑膜炎球菌免疫纳入常规疫苗接种计划。在高度多样化的亚太地区,很难估计 IMD 的流行病学情况,但现有证据表明 B 群血清型越来越占主导地位。疾病监测系统因国家而异。其中一些国家没有将 IMD 作为法定报告疾病。由于该地区缺乏足够的监测系统,因此 IMD 的风险和负担很可能被低估。随着新型联合脑膜炎球菌疫苗的出现和世界卫生组织到 2030 年消除细菌性脑膜炎的路线图,需要更好地了解亚太地区 IMD 的流行病学情况。